These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 19853024)

  • 1. Topical application of naltrexone facilitates reepithelialization of the cornea in diabetic rabbits.
    Zagon IS; Sassani JW; Carroll MA; McLaughlin PJ
    Brain Res Bull; 2010 Feb; 81(2-3):248-55. PubMed ID: 19853024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naltrexone and insulin are independently effective but not additive in accelerating corneal epithelial healing in type I diabetic rats.
    Klocek MS; Sassani JW; McLaughlin PJ; Zagon IS
    Exp Eye Res; 2009 Nov; 89(5):686-92. PubMed ID: 19576213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ocular surface abnormalities related to type 2 diabetes are reversed by the opioid antagonist naltrexone.
    Zagon IS; Sassani JW; Immonen JA; McLaughlin PJ
    Clin Exp Ophthalmol; 2014 Mar; 42(2):159-68. PubMed ID: 23777539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topically applied naltrexone restores corneal reepithelialization in diabetic rats.
    Klocek MS; Sassani JW; McLaughlin PJ; Zagon IS
    J Ocul Pharmacol Ther; 2007 Apr; 23(2):89-102. PubMed ID: 17444796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Naltrexone accelerates healing without compromise of adhesion complexes in normal and diabetic corneal epithelium.
    Zagon IS; Sassani JW; Myers RL; McLaughlin PJ
    Brain Res Bull; 2007 Apr; 72(1):18-24. PubMed ID: 17303503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetic keratopathy and treatment by modulation of the opioid growth factor (OGF)-OGF receptor (OGFr) axis with naltrexone: a review.
    McLaughlin PJ; Sassani JW; Klocek MS; Zagon IS
    Brain Res Bull; 2010 Feb; 81(2-3):236-47. PubMed ID: 19683562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Naltrexone, an opioid antagonist, facilitates reepithelialization of the cornea in diabetic rat.
    Zagon IS; Jenkins JB; Sassani JW; Wylie JD; Ruth TB; Fry JL; Lang CM; McLaughlin PJ
    Diabetes; 2002 Oct; 51(10):3055-62. PubMed ID: 12351447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reepithelialization of the human cornea is regulated by endogenous opioids.
    Zagon IS; Sassani JW; McLaughlin PJ
    Invest Ophthalmol Vis Sci; 2000 Jan; 41(1):73-81. PubMed ID: 10634604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical treatment with the opioid antagonist naltrexone facilitates closure of full-thickness wounds in diabetic rats.
    McLaughlin PJ; Pothering CA; Immonen JA; Zagon IS
    Exp Biol Med (Maywood); 2011 Oct; 236(10):1122-32. PubMed ID: 21917593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corneal safety of topically applied naltrexone.
    Zagon IS; Klocek MS; Sassani JW; Mauger DT; McLaughlin PJ
    J Ocul Pharmacol Ther; 2006 Oct; 22(5):377-87. PubMed ID: 17076633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of OGFr delays the onset and reduces the severity of diabetic ocular surface complications.
    Zagon IS; Sassani JW; Purushothaman I; McLaughlin PJ
    Exp Biol Med (Maywood); 2021 Mar; 246(5):629-636. PubMed ID: 33203224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of topical insulin to normalize corneal epithelial healing in diabetes mellitus.
    Zagon IS; Klocek MS; Sassani JW; McLaughlin PJ
    Arch Ophthalmol; 2007 Aug; 125(8):1082-8. PubMed ID: 17698755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of a novel naltrexone treatment for dry eye in type 1 diabetes.
    McLaughlin PJ; Sassani JW; Titunick MB; Zagon IS
    BMC Ophthalmol; 2019 Jan; 19(1):35. PubMed ID: 30691415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ocular surface complications in diabetes: The interrelationship between insulin and enkephalin.
    Purushothaman I; Zagon IS; Sassani JW; McLaughlin PJ
    Biochem Pharmacol; 2021 Oct; 192():114712. PubMed ID: 34324868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin treatment ameliorates impaired corneal reepithelialization in diabetic rats.
    Zagon IS; Sassani JW; McLaughlin PJ
    Diabetes; 2006 Apr; 55(4):1141-7. PubMed ID: 16567540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topical treatment with the opioid antagonist naltrexone accelerates the remodeling phase of full-thickness wound healing in type 1 diabetic rats.
    Immonen JA; Zagon IS; Lewis GS; McLaughlin PJ
    Exp Biol Med (Maywood); 2013 Oct; 238(10):1127-35. PubMed ID: 23986225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New therapeutic approaches in the treatment of diabetic keratopathy: a review.
    Abdelkader H; Patel DV; McGhee CNj; Alany RG
    Clin Exp Ophthalmol; 2011 Apr; 39(3):259-70. PubMed ID: 20973888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of exuberant granulation tissue and neovascularization in the rat cornea by naltrexone.
    Zagon IS; Klocek MS; Griffith JW; Sassani JW; Komáromy AM; McLaughlin PJ
    Arch Ophthalmol; 2008 Apr; 126(4):501-6. PubMed ID: 18413519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical naltrexone increases aquaporin 5 production in the lacrimal gland and restores tear production in diabetic rats.
    Diaz D; Sassani JP; Zagon IS; McLaughlin PJ
    Exp Biol Med (Maywood); 2024; 249():10175. PubMed ID: 38756167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topical aminocaproic acid facilitates reepithelialization of persistent epithelial defects.
    Williams PB; Crouch ER; Crouch ER; Mazaheri M
    Curr Eye Res; 1999 Feb; 18(2):150-7. PubMed ID: 10223660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.